Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Guy Young, MD
Incorporating Scientific Advances into Myelofibrosis Treatment Plans
Ruben Mesa, MD, FACP
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
Paul P. Doghramji, MD, FAAFP
Rami Komrokji, MD
Allan Platt, PA-C, MMSc
NSCLC Therapy Management and Biomarker Testing
Mark Socinski, MD
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
Neeraj Agarwal, MD
UsHERing in New Standards of Care on HER2+ and HER2-Low MBC
Reshma L. Mahtani, DO
Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making
Richard S. Finn, MD
Advancing Global Care with Emerging BTKi in Relapsed/Refractory CLL: Connecting Hematology Leaders to Worldwide Learners
Anthony Mato, MD, MSCE
Toby A. Eyre, MD, MBChB
Talha Munir, PhD
Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Viewpoint
Caron A. Jacobson, MD
Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Panel Discussion
Matthew Lunning, DO
Loretta J. Nastoupil, MD
Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
Patrick Forde, M.B.B.Ch.
Karen Reckamp, MS, MD
Loading...
Stay current with the best on medical education
We’re glad to see you’re enjoying AXISMedEd…but how about a more personalized experience?
Press cancel to remain on AXISMedEd. Press the link below or the continue button to keep going.
